Device Trial Radar · NCT05364502
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
Last checked: Nov 20, 2026Latest source record: Nov 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Dec 12, 2022
Primary completion
Jan 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Instylla, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 6, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
Conditions
- Arterial Bleeding in Solid Organs and Peripheral Arteries
Interventions
Embrace HES including Instylla™ Delivery Kit and Instylla™ MicrocatheterDevice
The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary safety endpointTime frame: Through 30 days post-index procedure
- Clinical SuccessTime frame: Within 30 days of the index procedure
- Technical SuccessTime frame: Immediately following index procedure
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Banner Health
Phoenix, Arizona
Memorial Health Services
Long Beach, California
Stanford University
Stanford, California
19 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.